Growth hormone therapy in heart failure: A novel therapy worthy of further consideration?

Expert Opinion on Investigational Drugs

Volumn 14, Issue 8, 2005, Pages 1009-1018

  Demers, Catherine ^a   McKelvie, Robert S ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b HHS General Hospital   (Canada)

Author keywords

Cardiac function; Exercise capacity; Growth hormone; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GHRELIN; GROWTH HORMONE; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ARTHRALGIA; BODY WEIGHT DISORDER; CARDIOVASCULAR SYSTEM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE EXACERBATION; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SIDE EFFECT; SURVIVAL; THORAX PAIN; TREATMENT OUTCOME; WEIGHT GAIN;

ADJUVANTS, PHARMACEUTIC; ANIMALS; GROWTH HORMONE; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 23644456191     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.8.1009     Document Type: Review

References (74)

1. THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl. J. Med. (1991) 325:293-302.
2. COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl. J. Med. (1991) 325:303-310.
3. THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. (1987) 316:1429-1435.
4. MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet (1999) 353:2001-2007.
5. CIBIS-II INVESTIGATORS AND COMMITTEES: The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet (1999) 353:9-13.
6. PACKER M, BRISTOW M, COHN J et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl. J. Med. (1996) 334:1349-1355.
7. ROSS J Jr, HONGO M: The role of hypertrophy and growth factors in heart failure. J. Card. Fail. (1997) 2:S121.
8. ROSS J Jr, RYOKE T: Effects of growth hormone and insulin-like growth factor I in experimental heart failure. Growth Horm. IGF Res. (1998) 8:159-161.
9. VOLTERRANI M, MANELLI F, CICOIRA M et al.: Role of growth hormone in chronic heart failure. Drugs (2000) 60:711-719.
10. SACCÀ L: Growth hormone therapy for heart failure: swimming against the stream. J. Card. Fail. (1999) 5:269-275.
11. FRYBBURG DA, GELFAND RA, BARRETT EJ: Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am. J. Physiol. (1991) 260:E499-E504.
12. FRYBURG DA: Insulin-like growth factor I exerts growth hormone-and-insulin-like actions on human muscle protein. Am. J. Physiol. (1994) 267:E331-E336.
13. ISGAARD J, TIVESTEN A, FRIBERG P, BENGTSSON BA: The Role of GH/IGF-1 axis for cardiac function and structure. Horm. Metab. Res. (1999) 31:50-54.
14. OSTERZIEL KJ, BLUM WF, STROHM O et al.: The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J. Clin. End. Metab. (2000) 85:1533-1539.
15. ISGAARD J, NILSSON A, VIKMAN K et al.: Growth hormone regulates the level of insulin-like growth factor I in rat skeletal muscle. J. Endocrinol. (1989) 120:107-112.
16. MATHEWS LS, ENBERG B, NORSTEDT G: Regulation of rat growth hormone receptor gene expression. J. Bio. Chem. (1989) 17:9905-9910.
17. ITO H, HIROE M, HIRATA Y et al.: Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation (1993) 87:1715-1721.
18. MAYOUX E, VENTURA-CLAPIER R, TIMSIT J et al.: Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ. Res. (1993) 72:57-64.
19. FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. New Engl. J. Med. (1996) 334:809-814.
20. TAJIMA M, WEINBERG EO, BARTUNEK J et al.: Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation (1999) 99:127-134.
21. FAZIO S, CITTADINI A, BIONDI B et al.: Cardiovascular effects of short-term growth hormone hypersecretion. J. Clin. Endocrin. Metab. (2000) 85:179-182.
22. CUNEO RC: Editorial: GH and cardiac failure. J. Clin. Endocrinol. Metab. (2001) 86:4638-4643.
23. CAPALDO B, GUARDASOLE V, PARDO F et al.: Abnormal vascular reactivity in growth hormone deficiency. Circulation (2001) 103:520-524.
24. HORNING B, MAIER V, DREXLER H: Physical training improves endothelial function in patients with chronic heart failure. Circulation (1996) 93:210-214.
25. FAZIO S, CITTADINI A, BIONDI B et al.: Growth hormone as a potential future therapy for congestive heart failure. Coron. Artery Dis. (1999) 10:383-388.
26. DE BOER H, BLOK GJ, VAN DER VEEN EA: Clinical aspects of growth hormone deficiency in adults. End. Rev. (1995) 16:63-86.
27. CUNEO RC, SALOMON F, WILES CM et al.: Growth hormone treatment in growth hormone deficient adults. I. Effects on muscle mass and strength. J. Appl. Physiol. (1991) 70:688-694.
28. CUNEO RC, SALOMON F, WILES CM et al.: Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J. Appl. Physiol. (1991) 70:695-700.
29. FRUSTACI A, PERRONE GA, GENTOLINI N et al.: Reversible dilated cardiomyopathy due to growth hormone deficiency. Am. J. Clin. Pathol. (1992) 97:503-511.
30. CUNEO RC, WILMHURST P, LOWY C et al.: Cardiac failure responding to growth hormone. Lancet (1989) I:838-839.
31. WHITEHEAD HM, BOREHAM C, McILRATH EM et al.: Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin. Endocrinol. (1992) 36:45-52.
32. FRUSTACI A, GENTILONI N, RUSSO MA: Growth hormone in the treatment of dilated cardiomyopathy. New Engl. J. Med. (1996) 335:672-673.
33. YANG R, BAUNTING S, GILLETT N et al.: Growth hormone improves cardiac performance in experimental heart failure. Circulation (1995) 92:262-267.
34. DUERR RL, HUANG S, MIRALIAKBAR HR et al.: Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J. Clin. Invest. (1995) 95:619-627.
35. AMBLER GR, JOHNSTON BM, MAXWELL L et al.: Improvement of doxorubicin-induced cardiomyopathy in rats treated with insulin-like growth factor-I. J. Cardiovasc. Res. (1993) 27:1369-1373.
36. DUERR RL, McKIRNAN MD, GIM RD et al.: Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation (1996) 93:2188-2196.
37. JIN H, YANG R, GILLETT N et al.: Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J. Cardiovas. Pahrmacol. (1995) 26:420-425.
38. SHEN Y-T, WIEDMANN RT, LYNCH JJ et al.: Growth hormone replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction. Am. J. Physiol. (1996) 271:H1721-H1726.
39. SHEN Y-T, WOLTMANN RF, APPLEBY S et al.: Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure. Am. J. Physiol. (1998) 274:H456-H466.
40. CITTADINI A, GROSSMAN JD, NAPOLI R et al.: Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J. Am. Coll. Cardiol. (1997) 29:1109-1116.
41. BUERKE M, MUROHARA T, SKURK C, et al.: Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc. Natl. Acad. Sci. USA (1995) 92:8031-8035.
42. SPINALE FG, HOUCK WV, PAN LC: Growth hormone supplementation with developing congestive heart failure: effects on left ventricular cellular structure and composition. Circulation (1998) 98:180 (Suppl. I).
43. TIMSIT J, RIOU B, BERTHERAT J et al.: Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern and myosin adenosine triphosphate activity of the rat left ventricle. J. Clin. Invest. (1990) 86:507-515.
44. KING MK, GAY DM, PAN LC et al.: Treatment with a growth hormone secretagogue in a model of developing heart failure. Effects on ventricular and myocyte function. Circulation (2001) 103:308-313.
45. O'DRISCOLL JG, GREEN DJ, IRELAND M et al.: Treatment of end-stage cardiac failure with growth hormone. Lancet (1997) 349:1068.
46. ROMAN DL, BOBILLO ER: Reversing idiopathic dilated cardiomyopathy with growth hormone: is this possible? Ann. Int. Med. (1997) 126:834.
47. GENTH-ZOTZ S, ZOTZ R, GEIL S et al.: Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation (1999) 99:18-21.
48. VOLTERRANI M, DESENZANI P, LORUSSO R et al.: Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet (1997) 349:1067-1068.
49. JOSE J, ZECHARIAH TU, GEORGE P: Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Ind. Heart J. (1999) 51:183-185.
50. SPALLAROSSA P, ROSSETTIN P, MINUTO F et al.: Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am. J. Cardiol. (1999) 84:430-433.
51. GIUSTINA A, VOLTERRANI M, MANELLI F, et al.: Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am. Heart J. (1999) 137:1035-1043.
52. CAPALDO B, LEMBO G, RENDINA V et al.: Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy. Eur. Heart J. (1998) 19:623-627.
53. OSTERZIEL KJ, STROHM O, SCHULER J et al.: Randomized, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet (1998) 351:1233-1237.
54. PERROT A, RANKE MB, DIETZ R et al.: Growth hormone treatment in dilated cardiomyopathy. J. Card. Surg. (2001) 16:127-131.
55. ISGAARD J, BERGH CH, CAIDAHL K et al.: A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. (1998) 19:1704-1711.
56. SMIT JWA, JANSSEN YJH, LAMB HJ et al.: Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J. Clin. Endocrinol. Metab. (2001) 86:4638-4643.
57. VAN THIEL SW, SMIT JWA, DE ROOS A et al.: Six-months of recombinant human GH therapy in patients with ischemic cardiac failure. Int. J. Cardiovasc. Imag. (2004) 20:53-60.
58. ACEVADO M, CORBALÁN R, CHAMORRO G et al.: Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function exercise capacity, and neurohormonal status. Int. J. Cardiol. (2003) 87:185-191.
59. NAPOLI R, GUARDASOLE V, MATARAZZO M et al.: Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J. Am. Coll. Cardiol. (2002) 39:90-95.
60. ADAMOPOULOS S, PARISSIS JT, GEORGIADIS M et al.: Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am. Heart J. (2002) 144:359-64.
61. ADAMOPOULOS S, PARISSIS JT, PARASKEVAIDIS I et al.: Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur. Heart J. (2003) 24:2186-96.
62. TAKALA J, RUOKONEN E, WEBSTER NR et al.: Increased mortality associated with growth hormone treatment in critically ill adults. New Engl. J. Med. (1999) 341:785-792.
63. MAITER D, WALKER JL, ADAM E: Differential regulation by growth hormone (GH) of insulin-like growth factor 1 and GH receptor/binding protein gene expression in rat liver. Endocrinology (1992) 130:3257-3264.
64. ISGAARD J, CARLSSON L, ISAKSSON OG et al.: Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor-1 messanger ribonucleic acid more effectively than continuous GH infusion. Endocrinology (1988) 123:2605-2610.
65. ANKER SD, CHUA TP, PONIKOWSKI P et al.: Hormonal changes in catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation (1997) 96:526-534.
66. ANKER SD, VOLTERRANI M, PFLAUM C-D et al.: Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol. (2001) 38:443-452.
67. CICOIRA M, KALRA PR, ANKER SD: Growth hormone resistance in chronic heart failure and its therapeutic implications. J. Card. Fail. (2003) 9:219-226.
68. NAGAYA N, KANGAWA K: Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Cur. Opin. Pharmacol. (2003) 3:146-151.
69. KOJIMA M, HOSODA H, DATE Y et al.: Ghrelin is a growth-hormone-releasing acylated peptidefrom stomach. Nature (1999) 402:656-660.
70. NAGAYA N, KANGAWA K: Ghrelin, a novel growth hormone-releasing peptide in the treatment of chronic heart failure. Regul. Pept. (2003) 114:71-77.
71. LOCATELLI V, ROSSONI G, SCHWEIGER F et al.: Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology (1999) 140:4024-4031.
72. NAGAYA N, MORYA J, YASUMURA Y et al.: Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation (2004) 110:3674-3679.
73. JAYASANKAR V, PIROLLI T, BISH L et al.: Targetted overexpression of growth hormone by adeno viral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy. J. Mol. Cell. Cardiol. (2004) 36:531-538.
74. JAYASANKER V, BISH L, PIROLLI T et al.: Local myocardial overexpression of growth hormone attenuates postinfarction remodeling and preserves cardiac function. Ann. Thorac. Surg. (2004) 77:2122-2129.